Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.58, Zacks reports. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.
Arcturus Therapeutics Trading Up 5.6%
Shares of NASDAQ:ARCT traded up $0.61 during trading on Monday, reaching $11.59. The company had a trading volume of 687,095 shares, compared to its average volume of 450,190. The company has a fifty day moving average of $11.87 and a two-hundred day moving average of $15.43. Arcturus Therapeutics has a 12 month low of $8.04 and a 12 month high of $45.00. The stock has a market capitalization of $314.33 million, a P/E ratio of -5.22 and a beta of 2.36.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the company. Wells Fargo & Company lowered their price objective on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Canaccord Genuity Group reduced their price objective on Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a research report on Monday, March 10th. HC Wainwright restated a "buy" rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Finally, BTIG Research set a $48.00 price target on Arcturus Therapeutics and gave the company a "buy" rating in a research note on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $59.20.
View Our Latest Research Report on Arcturus Therapeutics
About Arcturus Therapeutics
(
Get Free Report)
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
